Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review
Life · 13.12.2023 · 13 (12) · 2338
DOI: 10.3390/life13122338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 13.12.2023. Verfasst von Maria Tziastoudi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41334 Larisa, Greece. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) and chronic kidney disease (CKD) are associated with high mortality. In both disorders, impaired iron homeostasis, mostly in the form of a functional iron deficiency, is a frequent co-morbidity. In HF, functional iron deficiency and management by i.v. iron supplementation have been proven to affect both prognosis and functional capacity. In the same context, iron supplementation is routine for the adequate management of renal anemia in CKD. In numerous recent studies in HF and in CKD, sodium–glucose transporter 2 (SGLT2) inhibitor treatment has been proven to significantly reduce mortality. Furthermore, the same trials showed that these drugs alleviate iron deficiency and anemia. These effects of SGLT2 inhibitors may be due to an amelioration of inflammation with reduced interleukin-6 (IL-6) and to an enhancement of autophagy with increased sirtuin 1 (SIRT1), both associated with modified production of hepcidin and enhanced ferritinophagy. However, the exact pathogenic basis of the beneficial SGLT2 inhibitor action is not fully elucidated. Nevertheless, effects on iron homeostasis might be a potential explanatory mechanism for the powerful SGLT2 inhibitors’ cardiovascular and renal outcome benefits. In addition, the interaction between iron supplementation and SGLT2 inhibitors and its potential impact on prognosis remains to be clarified by future studies. This review represents a significant effort to explore the complex relationships involved, seeking to elucidate the intricate mechanisms by which SGLT2 inhibitors influence iron homeostasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41334 Larisa, Greece.
ORCID-Profile: Maria Tziastoudi, Theodoros Eleftheriadis, Ioannis Stefanidis
Zitieren
APA
Tziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., & Stefanidis, I. (2023). Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review. Life, 13(12), 2338. https://doi.org/10.3390/life13122338
Vancouver
Tziastoudi M, Pissas G, Golfinopoulos S, Filippidis G, Dousdampanis P, Eleftheriadis T, et al. Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review. Life. 2023;13(12):2338. doi:10.3390/life13122338
BibTeX
@article{Tziastoudi2023,
author = {Tziastoudi, Maria and Pissas, Georgios and Golfinopoulos, Spyridon and Filippidis, Georgios and Dousdampanis, Periklis and Eleftheriadis, Theodoros and Stefanidis, Ioannis},
title = {Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review},
journal = {Life},
year = {2023},
volume = {13},
number = {12},
pages = {2338},
doi = {10.3390/life13122338}
}
EUVIMED